CDNA
NEUTRALAnalystCareDx, Inc.
This is the 2026-09-30 snapshot — the signals and analysis for CDNA as of this single trading day.
View full CDNA research hub →Analysis
CareDx is experiencing high-conviction price discovery driven by a flawless fundamental turnaround, highlighted by 52% YoY revenue growth and the permanent resolution of its Medicare coverage overhang. The recent BTIG price target hike to $74 has catalyzed further institutional buying, perfectly aligning with the stock's PERFECT_STACK and MARKET_LEADER technical signals as it breaks to new 52-week highs. Operating in a RISK_ON (EARNINGS) macro regime where investors are aggressively rewarding strong corporate fundamentals and ignoring geopolitical noise, CDNA's combination of raised 2026 guidance and dominant relative strength (+33.2% vs SPY) cements its status as a structural market leader.
Fired Signals
Key Takeaways
- Actionable Thesis: CDNA is a high-conviction momentum buy, fueled by a massive Q2 earnings beat, raised 2026 guidance, and the removal of critical Medicare reimbursement risks.
- Key Risk: Valuation friction is emerging after a ~340% 1-year run, with some fundamental models suggesting intrinsic value is closer to the $50-$56 range, leaving the stock vulnerable to multiple compression if growth decelerates.
- What to Watch: Monitor the $49.60 technical line-in-the-sand for downside risk, while watching for continued institutional follow-through above the recent $65.53 high.